Hematologic Malignancies/BMT

自从上一次竞争性更新以来，血液恶性肿瘤和骨髓移植计划，以前的白血病-淋巴瘤/骨髓移植计划，在基于实验室和临床/‘翻译研究方面有了很大的扩展。多名研究人员加入了该计划，并启动了白血病生物学(白血病和淋巴瘤的基因组学/蛋白质组学和表观遗传学靶向)、白血病、骨髓瘤和淋巴瘤的靶向治疗(表观遗传学、MDM-2、Notch/泛素化和/或激酶途径)和预防异基因骨髓移植后复发的研究项目，此外，基础生物学方面的尖端研究和骨髓移植后在造血干细胞和移植物抗宿主疾病方面的出色翻译工作也得到了进一步扩大。同行评审的联邦和非联邦资助金额(白血病淋巴瘤协会、Damon Runyon等)已经大幅增加了。同行审查的直接资金从上次审查时的520万美元增加了一倍多，达到1340万美元，其中包括280万美元的NCI资金。在这一批款期内，该计划来自7个部门的36名成员出版了177份出版物，其中25.4%是计划内出版物，37.3%是计划间出版物。临床研究受益于著名临床研究人员的招聘，导致研究人员产生的治疗研究增加，我们还扩大了与业界的合作，研究新药。总的来说，这些举措正在导致患者在临床试验中获得更高的收益。

Since the last competing renewal, the Hematologic Malignancies and Bone Marrow Transplantation Program, formerly the Leukemia-Lymphoma/BMT Program, has greatly expanded in laboratory based and clinical/'translational research. Multiple Investigators have joined the Program and research projects have been Initiated In leukemia biology (the genomics/ proteomics and epigenetic targeting of leukemia and lymphoma), development of targeted therapies for leukemia, myeloma and lymphoma (epigenetic, MDM- 2, Notch/ ubiquitination and/ kinase pathways) and prevention of relapse after allogeneic BMT, In addition, the cutting edge research in basic biology and outstanding translational efforts in hematopoietic stem cells and graft-versus-host disease after BMT have been further expanded. The amount of peer reviewed funding, both federal and non-federal (Leukemia Lymphoma Society, Damon Runyon, etc.) has substantially increased. Peer-reviewed funding has more than doubled from $5.2 million at the last review to $13.4 million, including $2.8 million in NCI funding, in direct funding. Over this grant period, the 36 members of this program from seven departments have published 177 publications of which 25.4% are intra-programmatic and 37.3% are inter-programmatic. Clinical research has benefitted from the recruitment of prominent clinical investigators leading to an increase in Investigator-generated therapeutic studies, We have also expanded collaborations with industry to study novel drugs. Collectively, these Initiatives are leading to enhanced accrual of patients on clinical trials.